Q32 Bio Inc.
0T6G.L
Get informed when a big investor buys or sells
+ FollowMarket Cap$257.51M
Close$
$2.31
73.1% downside
Current Fair Value
73.1% downsideOvervalued by 73.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $257.51 Million |
|---|---|
| Enterprise Value | $155.80 Million |
| Dividend Yield | $- (-) |
| Earnings per Share | $2.42 |
| Beta | -0.33 |
| Outstanding Shares | 20,342,345 |
Return
| Return on Equity | 31.90% |
|---|---|
| Return on Assets | 29.16% |
| Return on Invested Capital | 19.67% |
Valuation & Multiples
| P/E Ratio | 3.1 |
|---|---|
| PEG | -54.18 |
| Price to Sales | 4.3 |
| Price to Book Ratio | 1.72 |
| Enterprise Value to Revenue | 2.9 |
| Enterprise Value to EBIT | 7.17 |
| Enterprise Value to Net Income | 4 |
| Total Debt to Enterprise | 0.03 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 5, 2026
EPS Estimate
$-0.54
Average shareholder expectationRevenue Estimate
$1.00 M
Average shareholder expectationNext Earnings Call
Expected Date
November 5, 2026
EPS Estimate
$-0.33
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Sentiment (Put/Call)
No data available for the latest quarter.
Institutional Ownership
No data available for the latest quarter.
ESG Score
No data
About Q32 Bio Inc.
131 employees
CEO: Arthur Tzianabos homology medicines is a genetic medicines company translating proprietary gene editing and gene therapy technologies into novel treatments for patients with rare diseases.